Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Payables (2017 - 2025)

Dianthus Therapeutics (DNTH) has 7 years of Payables data on record, last reported at $6.7 million in Q3 2025.

  • For Q3 2025, Payables fell 11.45% year-over-year to $6.7 million; the TTM value through Sep 2025 reached $6.7 million, down 11.45%, while the annual FY2024 figure was $4.6 million, 75.44% up from the prior year.
  • Payables reached $6.7 million in Q3 2025 per DNTH's latest filing, up from $5.4 million in the prior quarter.
  • Across five years, Payables topped out at $8.3 million in Q1 2025 and bottomed at $813000.0 in Q2 2023.
  • Average Payables over 4 years is $3.7 million, with a median of $2.6 million recorded in 2024.
  • Peak YoY movement for Payables: tumbled 75.66% in 2023, then surged 453.1% in 2024.
  • A 4-year view of Payables shows it stood at $1.2 million in 2022, then soared by 123.65% to $2.6 million in 2023, then skyrocketed by 75.44% to $4.6 million in 2024, then soared by 46.43% to $6.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $6.7 million in Q3 2025, $5.4 million in Q2 2025, and $8.3 million in Q1 2025.